Premature epiphyseal growth plate arrest after isotretinoin therapy for high-risk neuroblastoma: A case series and review of the literature.
isotretinoin
neuroblastoma
pediatric hematology/oncology
premature epiphyseal growth arrest
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
07
10
2019
revised:
15
01
2020
accepted:
04
02
2020
pubmed:
10
5
2020
medline:
8
9
2020
entrez:
10
5
2020
Statut:
ppublish
Résumé
Vitamin A-derived retinoids have been reported to cause skeletal abnormalities ranging from hypercalcemia to premature epiphyseal closure. Isotretinoin is a retinoid used as standard therapy for high-risk neuroblastoma and has been reported to cause premature epiphyseal growth plate arrest. We identified patients from the Children's Hospital Los Angeles (CHLA) database with high-risk neuroblastoma diagnosed from 1991 to 2018 who experienced premature epiphyseal growth plate arrest and compared their characteristics to other patients with high-risk neuroblastoma. We then performed a literature review of this complication. Data collection included diagnosis age of neuroblastoma, presentation age, agent of exposure, dose, exposure range, and skeletal deformity. Among 216 patients, high-risk neuroblastoma was diagnosed before age of five years (n = 165), between ages of 5 and 10 years (n = 41), and after 10 years of age (n = 13). Three out of 216 patients developed premature epiphyseal growth arrest after isotretinoin exposure (overall incidence = 1.38%). The incidence of bony abnormalities was significantly higher in patients diagnosed in 5- to 10-year age group than in other two groups (P = 0.014). Literature review identified eight additional patients with neuroblastoma who presented with retinoid associated skeletal abnormalities. The median range of isotretinoin exposure for these 11 patients was between 6.5 and 7.625 years (range, 2-14) with no cases of isotretinoin therapy completion before age 5 years. Bone toxicity associated with isotretinoin exposure is a concern. Growth plate arrest is a serious adverse effect that is attributable to isotretinoin therapy. Our findings suggest the prepubescent growth plate may be most at risk, and we recommend special attention to this population.
Sections du résumé
BACKGROUND
Vitamin A-derived retinoids have been reported to cause skeletal abnormalities ranging from hypercalcemia to premature epiphyseal closure. Isotretinoin is a retinoid used as standard therapy for high-risk neuroblastoma and has been reported to cause premature epiphyseal growth plate arrest.
PROCEDURE
We identified patients from the Children's Hospital Los Angeles (CHLA) database with high-risk neuroblastoma diagnosed from 1991 to 2018 who experienced premature epiphyseal growth plate arrest and compared their characteristics to other patients with high-risk neuroblastoma. We then performed a literature review of this complication. Data collection included diagnosis age of neuroblastoma, presentation age, agent of exposure, dose, exposure range, and skeletal deformity.
RESULTS
Among 216 patients, high-risk neuroblastoma was diagnosed before age of five years (n = 165), between ages of 5 and 10 years (n = 41), and after 10 years of age (n = 13). Three out of 216 patients developed premature epiphyseal growth arrest after isotretinoin exposure (overall incidence = 1.38%). The incidence of bony abnormalities was significantly higher in patients diagnosed in 5- to 10-year age group than in other two groups (P = 0.014). Literature review identified eight additional patients with neuroblastoma who presented with retinoid associated skeletal abnormalities. The median range of isotretinoin exposure for these 11 patients was between 6.5 and 7.625 years (range, 2-14) with no cases of isotretinoin therapy completion before age 5 years.
CONCLUSION
Bone toxicity associated with isotretinoin exposure is a concern. Growth plate arrest is a serious adverse effect that is attributable to isotretinoin therapy. Our findings suggest the prepubescent growth plate may be most at risk, and we recommend special attention to this population.
Substances chimiques
Isotretinoin
EH28UP18IF
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28236Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Chen SC, Murphy D, Sastry J, Shaikh MG. Predicting, monitoring, and managing hypercalcemia secondary to 13-cis-retinoic acid therapy in children with high-risk neuroblastoma. J Pediatr Hematol Oncol. 2015;37(6):477-481.
Zhao S, Goodson NJ. Diffuse idiopathic skeletal hyperostosis and isotretinoin in cystic acne. BMJ Case Rep. 2015;2015. https://doi.org/10.1136/bcr-2015-209775.
DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol. 1995;131(11):1263-1267.
Pease CN. Focal retardation and arrestment of growth of bones due to vitamin A intoxication. JAMA. 1962;182:980-985.
Prendiville J, Bingham EA, Burrows D. Premature epiphyseal closure-a complication of etretinate therapy in children. J Am Acad Dermatol. 1986;15(6):1259-1262.
Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27(7):1007-1013.
Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165-1173.
Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008-3017.
Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14(10):999-1008.
Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-1334.
Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011;29(33):4351-4357.
Cross SF, Dalla Pozza L, Munns CF. Hypercalcemia and osteoblastic lesions induced by 13-Cis-retinoic acid mimicking relapsed neuroblastoma. Pediatr Blood Cancer. 2009;53(4):666-668.
Sato Y, Kuwashima S, Kurosawa H, Sugita K, Fukushima K, Arisaka O. 13-cis-retinoic acid-associated bone marrow edema in neuroblastoma. Pediatr Blood Cancer. 2012;59(3):589-590.
Nishimura G, Mugishima H, Hirao J, Yamato M. Generalized metaphyseal modification with cone-shaped epiphyses following long-term administration of 13-cis-retinoic acid. Eur J Pediatr. 1997;156(6):432-435.
Hoemberg S, Reinhard H. Growth failure caused by premature epiphyseal closure in a child treated with isotretinoin for neuroblastoma. Klin Padiatr. 2017;229:175-176.
Noyes JJ, Levine MA, Belasco JB, Mostoufi-Moab S. Premature epiphyseal closure of the lower extremities contributing to short stature after cis-retinoic acid therapy in medulloblastoma: a case report. Horm Res Paediatr. 2016;85(1):69-73.
Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009;23(2):125-143.
Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369-386.
Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979-2015. Paediatr Drugs. 2017;19(6):577-593.
Steele RG, Lugg P, Richardson M. Premature epiphyseal closure secondary to single-course vitamin A therapy. Aust N Z J Surg. 1999;69(11):825-827.
Milstone LM, McGuire J, Ablow RC. Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol. 1982;7(5):663-666.
Lawson JP, McGuire J. The spectrum of skeletal changes associated with long-term administration of 13-cis-retinoic acid. Skeletal Radiol. 1987;16(2):91-97.
Pittsley RA, Yoder FW. Retinoid hyperostosis. Skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med. 1983;308(17):1012-1014.
Marini JC, Hill S, Zasloff MA. Dense metaphyseal bands and growth arrest associated with isotretinoin therapy. Am J Dis Child. 1988;142(3):316-318.
Luthi F, Eggel Y, Theumann N. Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain. Joint Bone Spine. 2012;79(3):314-316.
Ruby LK, Mital MA. Skeletal deformities following chronic hypervitaminosis A: a case report. J Bone Joint Surg Am. 1974;56(6):1283-1287.
Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018;372(2):195-209.
Peinemann F, van Dalen EC, Enk H, Berthold F. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2017;8:Cd010685.
Simon T, Hero B, Schulte JH, et al. 2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors. Klin Padiatr. 2017;229(3):147-167.
Damodar Reddy C, Guttapalli A, Adamson PC, et al. Anticancer effects of fenretinide in human medulloblastoma. Cancer Lett. 2006;231(2):262-269.
Chang Q, Chen Z, You J, et al. All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line. J Neurooncol. 2007;84(3):263-267.
Bassani B, Bartolini D, Pagani A, et al. Fenretinide (4-HPR) targets caspase-9, ERK 1/2 and the Wnt3a/beta-catenin pathway in medulloblastoma cells and medulloblastoma cell spheroids. PLoS One. 2016;11(7):e0154111.